Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 20 studies | 23% ± 8% | |
memory B cell | 12 studies | 24% ± 8% | |
naive B cell | 11 studies | 26% ± 8% | |
natural killer cell | 8 studies | 23% ± 6% | |
classical monocyte | 8 studies | 24% ± 7% | |
non-classical monocyte | 7 studies | 27% ± 9% | |
mast cell | 6 studies | 27% ± 8% | |
regulatory T cell | 6 studies | 19% ± 2% | |
CD4-positive, alpha-beta T cell | 5 studies | 21% ± 5% | |
dendritic cell | 5 studies | 41% ± 7% | |
gamma-delta T cell | 5 studies | 20% ± 4% | |
T cell | 4 studies | 20% ± 3% | |
endothelial cell | 4 studies | 22% ± 7% | |
CD16-negative, CD56-bright natural killer cell, human | 4 studies | 26% ± 7% | |
conventional dendritic cell | 4 studies | 27% ± 9% | |
immature B cell | 4 studies | 23% ± 5% | |
macrophage | 4 studies | 23% ± 7% | |
CD8-positive, alpha-beta T cell | 4 studies | 18% ± 3% | |
mucosal invariant T cell | 3 studies | 22% ± 3% | |
myeloid cell | 3 studies | 32% ± 2% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 20% ± 2% | |
precursor B cell | 3 studies | 19% ± 2% | |
innate lymphoid cell | 3 studies | 25% ± 7% | |
fibroblast | 3 studies | 19% ± 2% | |
T follicular helper cell | 3 studies | 20% ± 1% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 5 studies | 20% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 100% | 4350.61 | 170 / 170 | 100% | 61.54 | 459 / 459 |
esophagus | 100% | 3286.01 | 1444 / 1445 | 100% | 65.90 | 183 / 183 |
prostate | 100% | 5135.36 | 245 / 245 | 100% | 50.01 | 501 / 502 |
ovary | 100% | 3418.79 | 180 / 180 | 100% | 50.11 | 429 / 430 |
skin | 100% | 2952.58 | 1806 / 1809 | 100% | 47.78 | 471 / 472 |
intestine | 100% | 5156.05 | 966 / 966 | 100% | 44.85 | 525 / 527 |
stomach | 100% | 3066.77 | 358 / 359 | 100% | 50.92 | 285 / 286 |
lung | 100% | 6861.00 | 577 / 578 | 99% | 51.28 | 1148 / 1155 |
breast | 100% | 3476.62 | 459 / 459 | 99% | 43.53 | 1105 / 1118 |
thymus | 100% | 3752.98 | 652 / 653 | 99% | 43.52 | 597 / 605 |
bladder | 100% | 4974.57 | 21 / 21 | 98% | 47.19 | 495 / 504 |
pancreas | 98% | 2335.88 | 323 / 328 | 98% | 63.08 | 174 / 178 |
kidney | 100% | 4493.11 | 89 / 89 | 95% | 46.91 | 858 / 901 |
liver | 96% | 2433.10 | 216 / 226 | 99% | 44.63 | 402 / 406 |
adrenal gland | 100% | 3207.71 | 258 / 258 | 82% | 18.37 | 189 / 230 |
brain | 30% | 374.48 | 780 / 2642 | 71% | 11.88 | 504 / 705 |
eye | 0% | 0 | 0 / 0 | 100% | 42.10 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 176.48 | 29 / 29 |
spleen | 100% | 8529.82 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 85.80 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 46.20 | 1 / 1 |
adipose | 100% | 3823.88 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3071.21 | 1329 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 9064.24 | 922 / 929 | 0% | 0 | 0 / 0 |
heart | 94% | 1925.07 | 806 / 861 | 0% | 0 | 0 / 0 |
muscle | 91% | 1661.12 | 733 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006954 | Biological process | inflammatory response |
GO_0033554 | Biological process | cellular response to stress |
GO_0045087 | Biological process | innate immune response |
GO_0002467 | Biological process | germinal center formation |
GO_0034097 | Biological process | response to cytokine |
GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
GO_0002268 | Biological process | follicular dendritic cell differentiation |
GO_0030198 | Biological process | extracellular matrix organization |
GO_0048536 | Biological process | spleen development |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0038061 | Biological process | non-canonical NF-kappaB signal transduction |
GO_0048511 | Biological process | rhythmic process |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0033257 | Cellular component | Bcl3/NF-kappaB2 complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NFKB2 |
Protein name | Nuclear factor NF-kappa-B p100 subunit Nuclear factor NF-kappa-B p100 subunit (DNA-binding factor KBF2) (H2TF1) (Lymphocyte translocation chromosome 10 protein) (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2) (Oncogene Lyt-10) (Lyt10) [Cleaved into: Nuclear factor NF-kappa-B p52 subunit] |
Synonyms | LYT10 |
Description | FUNCTION: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. In a non-canonical activation pathway, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B heterodimeric RelB-p52 complex is a transcriptional activator. The NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p100 and generation of p52 by a cotranslational processing. The proteasome-mediated process ensures the production of both p52 and p100 and preserves their independent function. p52 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. p52 and p100 are respectively the minor and major form; the processing of p100 being relatively poor. Isoform p49 is a subunit of the NF-kappa-B protein complex, which stimulates the HIV enhancer in synergy with p65. In concert with RELB, regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. . |
Accessions | ENST00000652277.1 [Q00653-4] Q00653 A0A1P8C958 ENST00000661543.1 [Q00653-1] ENST00000369966.8 [Q00653-1] ENST00000189444.11 [Q00653-4] ENST00000428099.6 [Q00653-4] |